



## PATENT APPLICATION

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q85416

Motonori MIYAKAWA, et al.

Appln. No.: 10/518,405

Group Art Unit: Not Yet Assigned

Confirmation No.: 8028

Examiner: Not Yet Assigned

Filed: November 18, 2005

For:

ANDROGEN RECEPTOR AGONISTS

## REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

ATTN: Office of Initial Patent Examination

Filing Receipt Correction

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

We enclose a copy of the Official Filing Receipt for the above-identified application and request the following corrections:

TOT CLMS

<del>13</del> 29

**Foreign Applications** 

**JAPAN** 

179088/2002

June 19, 2002

## REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

Appln. No.: 10/518,405 Atty. Docket No.: Q85416

Verification for the requested corrections is indicated on the Declaration and Assignment filed November 18, 2005 and December 17, 2004 letter to the Commissioner for Patents.

Respectfully submitted,

Registration No. 30,951

SUGHRUE MION, PLLC Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE 23373
CUSTOMER NUMBER

Date: May31, 2006



# FILING RECEIPT EASE DATE STAMP AND RETURN TO US - BOX 235X

In re application of

Motonori MIYAKAWA, et al.

Appln. No.: 10/518,405

Confirmation No.: 8028

Filed: November 18, 2005

For: ANDROGEN RECEPTOR AGONISTS

PAPER(S) FILED ENTITLED:

1. Request for Corrected Official Filing Receipt

2. Marked up copy of Official Filing Receipt

3. Copy of December 17, 2004 letter to the Commissioner for Patents

4. Declaration and Power of Attorney

5. Assignment

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373
CUSTOMER NUMBER


DOCKET NO.: Q85416

ATTORNEY/SEC: Susan J. Mack/laj

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

Date Filed: May 31, 2006



UNITED STATES DEPARTMENT OF COMMERCE UNITED STATES DEPARTMENT OF COMMI United States Patent and Trademark Office Addrew COMMISSIONER FOR PATENTS P.O. Box 1430 Alexandria, Viginia 22313-1450 www.uspto.gov

FILING OR 371 APPL NO. **ART UNIT** FIL FEE REC'D ATTY.DOCKET NO **DRAWINGS** TOT CLMS IND CLMS (c) DATE 10/518,405 11/18/2005 1614 2510 Q85416

**CONFIRMATION NO. 8028** 

**FILING RECEIPT** 

\*OC000000017912517\*

23373 SUGHRUE MION, PLLC 2100 PENNSYLVANIA AVENUE, N.W. SUITE 800 WASHINGTON, DC 20037

Date Mailed: 01/31/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE. NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

#### Applicant(s)

Motonori Miyakawa, Kyoto, JAPAN: Yuji Sumita, Kyoto, JAPAN; 🛂 Kazuyuki Furuya, Kyoto, JAPAN; Kiyonoshin Ichikawa, Kyoto, JAPAN; Noriko Yamamoto, Kyoto, JAPAN; Seiji Amano, Kyoto, JAPAN: Hiroaki Nejishima, Kyoto, JAPAN; Keigo Hanada, Shiga, JAPAN;

#### **Assignment For Published Patent Application**

KAKEN PHARMACEUTICAL CO., LTD., TOKYO, JAPAN

Power of Attorney: The patent practitioners associated with Customer Number 23373.

#### Domestic Priority data as claimed by applicant

This application is a 371 of PCT/JP03/07799 06/19/2003

Foreign Applications

179088/2002 June 19,2002 TAPAN

Projected Publication Date: 05/04/2006

Non-Publication Request: No

Early Publication Request: No

**Title** 

Androgen receptor agonists

**Preliminary Class** 

514

## PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15

#### **GRANTED**

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted

under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

#### **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).





Susan J. Mack T (202) 663-7943 smack@sughrue.com

December 17, 2004

2100 Pennsylvania Avenue, NW Washington, DC 20037-3213 T 202.293.7060

F 202.293.7060

401 Castro Street Mountain View, CA 94041-2007 T 650.625.8100 F 650.625.8110

AIG Bidg. 14F 1–1–3 Marunouchi Chiyoda–ku Tokyo 100–0005 Japan T 03.5220.0200

www.sughrue.com

F 03.5220.0222

MAIL STOP PCT

Commissioner for Patents P.O. BOX 1450 Alexandria, VA 22313-1450

PCT/JP03/07799 -filed June 19, 2003

Re:

Application of Motonori MIYAKAWA, Yuji SUMITA, Kazuyuki FURUYA,

Kiyonoshin ICHIKAWA, Noriko YAMAMOTO, Keigo HANADA, Seiji

AMANO and Hiroaki NEJISHIMA ANDROGEN RECEPTOR AGONISTS

Assignee:

KAKEN PHARMACEUTICAL CO., LTD.

Our Ref:

Q85416

#### Dear Sir:

The following documents and fees are submitted herewith in connection with the above application for the purpose of entering the National stage under 35 U.S.C. §371 and in accordance with the Patent Cooperation Treaty:

- ☑ a copy of the executed Declaration and Power of Attorney.
- ☐ an English translation of the International Application.
- ☑ 18 sheet(s) of drawings.
- ☑ a copy of the executed Assignment and PTO 1595 form.
- ☑ a PTO/SB/08 A & B (modified) listing the ISR/IPER references.
- ☑ a Preliminary Amendment.
- ☑ it is expressly requested that the national stage of processing be commenced immediately in accordance with 35 U.S.C. § 371(f)

It is assumed that copies of the International Application, the International Search Report and cited references, the International Preliminary Examination Report, and any Articles 19 and 34 amendments as required by §371(c) will be supplied directly by the International Bureau, but if further copies are needed, the undersigned will undertake to provide them upon request.



National Stage Application of PCT/JP03/07799 -filed June 19, 2003

Q85416

The Government filing fee is calculated as follows:

Total claims29	- 20	=	9	x	\$50.00	=	\$450.00
Independent claims 1	- 3	=		X	\$200.00	=	\$.00
Filing Fee						_	\$300.00
Examination Fee					-		\$200.00
Search Fee							\$500.00
Multiple Dependent Claim Fee							\$360.00
TOTAL FILING FEE							1,810.00
Recordation of Assignment							\$40.00
TOTAL FEE							\$1,850.00

Checks for the statutory filing fee of \$1,810.00 and Assignment recordation fee of \$40.00 are attached. The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this transmittal letter is attached.

Priority is claimed from:

$\sim$				
( )	ΩH	ınt	rν	

Application No

Filing Date

Japan

179088/2002

June 19, 2002

Respectfully submitted,

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE 23373 CUSTOMER NUMBER

Date: December 17, 2004

Registration No. 30,951

#### DECLARATION AND POWER O. STORNEY FOR UTILITY OR DESIGN P. SNT APPLICATION (37 CFR 1.63)

As a below named inventor, I hereby declare that: My residence, mailing address, and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

ANDROGEN RECEPTOR AGONISTS

I hereby state that I have reviewed and understand the conte	was filed onJune 19, 2003 as United States Application Number or PCT International Application Number PCT/JP03/07799 (Confirmation No), and was amended on (if applicable).  ents of the above identified application, including the claims, as amended.
	s material to patentability as defined in 37 CFR 1.56, including for ich became available between the filing date of the prior application and on-in-part application.
or plant breeder's rights certificate(s), or 365(a) of any PCT than the United States of America, listed below and have a	(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's international application(s) which designated at least one country other lso identified below, by checking the box, any foreign application(s) for particular international application(s) having a filing date before that of the

		•	Priority	Claimed
Prior Foreign Application Number(s)	Country	Foreign Filing Date	Yes	No
179088/2002	Japan	June 19, 2002	<b>\Sigma</b>	

I hereby claim domestic priority benefits under 35 United States Code §120 of any United States application(s), §119(e) of any United States provisional application(s), or §365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in a listed prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge my duty to disclose any information material to the patentability of this application as defined in 37 C.F.R. 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Prior U.S. or International Application Number(s)

U.S. or International Filing Date

Status

I hereby appoint all attorneys of SUGHRUE MION, PLLC who are listed under the USPTO Customer Number shown below as my attorneys to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith, recognizing that the specific attorneys listed under that Customer Number may be changed from time to time at the sole discretion of Sughrue Mion, PLLC, and request that all correspondence about the application be addressed to the address filed under the same USPTO Customer Number.

23373

PATENT TRADEMARK OFFICE

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

NAME OF SOLE OR FIRST INVI	OR:			•		
Given Name (first and middle [if any]) Motonori Family Name or Surname MIYAKAWA						
Inventor's Signature	Mynkower		Date	11/4/04		
Residence: City Kyoto	State RESEARCH LABORATORIE	Country Japan	·m · O · I	Citizenship Japanese		
Mailing Address: 14, Shinomiya	aminamigawara-cho, Y	amashina-ku, Kyoto	o-shi,	Kyoto 607-8042 Japan		
City Kyoto	State	Zip 607-8042		Country Japan		
NAME OF SECOND INVENTOR:			·			
Given Name (first and middle [if any])		Family Name or Surnam	ne			
Inventor's Signature	Ţ	·	Date			
Residence: City	State	Country		Citizenship		
Mailing Address:	T	·	·	· · · · · · · · · · · · · · · · · · ·		
City	State	Zip		Country		
NAME OF THIRD INVENTOR:						
Given Name (first and middle [if any])		Family Name or Surnam	ne			
Inventor's Signature	T	1	Date			
Residence: City	State	Country		Citizenship		
Mailing Address:						
City	State	Zip		Country		
NAME OF FOURTH INVENTOR:		·	· / · · · · · · · · · · · · · · · · · ·			
Given Name (first and middle [if any])		Family Name or Surnam	e			
Inventor's Signature	Γ		Date			
Residence: City	State	Country		Citizenship		
Mailing Address:		T				
City	State	Zip		Country		
NAME OF FIFTH INVENTOR:		<del></del>				
Given Name (first and middle [if any])		Family Name or Surname	e			
Inventor's Signature			Date			
Residence: City	State	Country		Citizenship		
Mailing Address:						
City	State	Zip		Country		
City	State	Zip		Country		

## DECLARATION AND POWER OF FORNEY FOR UTILITY OR DESIGN PA NT APPLICATION (37 CFR 1.63)

As a below named inventor, I hereby declare that: My residence, mailing address, and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

ANDROGEN RECEPTOR AGONISTS	
OIPE	
the application of which is attached heretoMAY 3 1 2006 OR	was filed on June 19, 2003 as United States Application Number or PCT International Application Number PCT/JP03/07799, (Confirmation No), and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part application(s), material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application(s) which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application(s) having a filing date before that of the application on which priority is claimed.

		•	Priority	Claimed
Prior Foreign Application Number(s)	Country	Foreign Filing Date	Yes	No
			<b>X</b> I	<b>-</b>
179088/2002	Japan	<u>June 19, 2002</u>		

I hereby claim domestic priority benefits under 35 United States Code §120 of any United States application(s), §119(e) of any United States provisional application(s), or §365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in a listed prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge my duty to disclose any information material to the patentability of this application as defined in 37 C.F.R. 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Prior U.S. or International Application Number(s)	U.S. or International Filing Date	Status
	•	

I hereby appoint all attorneys of SUGHRUE MION, PLLC who are listed under the USPTO Customer Number shown below as my attorneys to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith, recognizing that the specific attorneys listed under that Customer Number may be changed from time to time at the sole discretion of Sughrue Mion, PLLC, and request that all correspondence about the application be addressed to the address filed under the same USPTO Customer Number.



PATENT TRADEMARK OFFICE

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

NAME OF SOLE OR FIRST INVI	OR:			•	
Given Name (first and middle [if any]) Keigo Family Name or Surname HANADA					
Inventor's Signature	yo Hanas	la	Date	November 4, 2004	
Residence: City Shiga	State	Country Japan		Citizenship Japanese	
Mailing Address: 2-1-38, Hira	i, Kusatsu-shi, Shig	a 525-0023 Japan	<del></del>	•	
City Shiga	State	Zip 525-0023		Country Japan	
NAME OF SECOND INVENTOR:		·	<u>.</u>		
Given Name (first and middle [if any])		Family Name or Surnam	ie .		
Inventor's Signature	<u> </u>		Date		
Residence: City	State	Country	<u> </u>	Citizenship	
Mailing Address:	<del></del>	·			
City	State	Zip		Country	
NAME OF THIRD INVENTOR:				Country	
Given Name (first and middle [if any])		Family Name or Surnam	e		
Inventor's Signature			Date		
Residence: City	State	Country	•	Citizenship	
Mailing Address:	<u></u>	•	<del></del>		
City	State	Zip		Country	
NAME OF FOURTH INVENTOR:					
Given Name (first and middle [if any])		Family Name or Surname	e		
Inventor's Signature			Date		
Residence: City	State	Country		Citizenship	
Mailing Address:					
City	State	Zip		Country	
NAME OF FIFTH INVENTOR:					
Given Name (first and middle [if any])		Family Name or Surname	<u> </u>		
Inventor's Signature			Date		
Residence: City	State	Country		Citizenship	
Mailing Address:	· · · · · · · · · · · · · · · · · · ·		<del></del>		
City	State	Zip		Country	

## DECLARATION AND POWER O. STORNEY FOR UTILITY OR DESIGN P. NT APPLICATION (37 CFR 1.63)

As a below named inventor, I hereby declare that: My residence, mailing address, and citizenship are as stated below next to my name. I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

ANDROGEN RECEPTOR AGONISTS

the application of which	
is attached hereto  MAY 3 1 2006	Was filed on June 19, 2003 as United States Application Number or PCT International Application Number PCT/JP03/07799 (Confirmation No), and was amended on (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified application, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56, including for continuation-in-part application(s), material information which became available between the filing date of the prior application and the national or PCT international filing date of the continuation-in-part application.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or (f), or 365(b) of any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or 365(a) of any PCT international application(s) which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application(s) for patent, inventor's or plant breeder's rights certificate(s), or any PCT international application(s) having a filing date before that of the application on which priority is claimed.

		•	Priority	Claimed
Prior Foreign Application Number(s)	Country	Foreign Filing Date	Yes	No
179088/2002	Japan	June 19, 2002		

I hereby claim domestic priority benefits under 35 United States Code §120 of any United States application(s), §119(e) of any United States provisional application(s), or §365(c) of any PCT International application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in a listed prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge my duty to disclose any information material to the patentability of this application as defined in 37 C.F.R. 1.56 which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

Prior U.S. or International Application Number(s)	U.S. or International Filing Date	Status
	`	
	·	<del></del>

I hereby appoint all attorneys of SUGHRUE MION, PLLC who are listed under the USPTO Customer Number shown below as my attorneys to prosecute this application and to transact all business in the United States Patent and Trademark Office connected therewith, recognizing that the specific attorneys listed under that Customer Number may be changed from time to time at the sole discretion of Sughrue Mion, PLLC, and request that all correspondence about the application be addressed to the address filed under the same USPTO Customer Number.



PATENT TRADEMARK OFFICE

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

NAME OF SOLE OR FIRST INVI	. OR:		
Given Name			
(first and middle [if any]) Yuji		Family Name or Surname	E SUMITA
Inventor's Signature	Tuji Sumita		Date November 4, 2004
Desidence Che Vesta			
Residence: City Kyoto	State RESEARCH LABORATORIE	Country Japan	Citizenship Japanese
			-shi, Kyoto 607-8042 Japan
			3117 1, 000 00. 00 10 00 00.
City Kyoto	State	Zip 607-8042	Country Japan
NAME OF SECOND INVENTOR:	· · · · · · · · · · · · · · · · · · ·		<del></del>
Given Name  (first and middle (if anyl) Kagy	1-2	The settle NT Occursome	
(first and middle [if any]) Kazu		Family Name or Surname	FURUYA
Inventor's Signature Kazuyi	iki Furuya		Date November 4, 2004
Residence: City Kyoto	State	Country Japan	Citizenship Japanese
c/o CENTRAL	RESEARCH LABORATORIE	S, KAKEN PHARMACEU	TICAL CO., LTD. of
Mailing Address: 14, Shinomiy	aminamigawara-cho, Y	amashina-ku, Kyoto	-shi, Kyoto 607-8042 Japan
City Kyoto	State	Zip 607-8042	Country Japan
NAME OF THIRD INVENTOR:	Otaco	1 24p 30. 00	Country Super.
Given Name			
(first and middle [if any]) Kiyo	noshin	Family Name or Surname	: ICHIKAWA
Inventor's Signature Kirches	hin Zchikawa		Date November 4, 2004
Residence: City Kyoto	State	Country Japan	. Citizenship Japanese
	RESEARCH LABORATORIE		
Mailing Address: 14, Shinomiya			
City Kyoto	State	Zip 607-8042	Country
NAME OF FOURTH INVENTOR:	State	Zip 607-8042	Country Japan
Given Name			
(first and middle [if any]) Noril	ςo	Family Name or Surname	YAMAMOTO
Inventor's Signature Nork	o Yamamoto		Date November 4, 2004
Thromas displaced 1 NU1	O TOWNSON IV		Date November 4, 2004
Residence: City Kyoto	State	Country Japan	Citizenship Japanese
	RESEARCH LABORATORIE		
Mailing Address: 14, Shinomiya	aminamigawara-cho, y	amashina-ku, Kyoto-	-shi, Kyoto 607-8042 Japan
City Kyoto	State	Zip 607-8042	Country Japan
NAME OF FIFTH INVENTOR:			-
Given Name			
(first and middle [if any]) Seiji	<u>-</u> 1	Family Name or Surname	AMANO
Inventor's Signature Sei.	ji Amano		Date November 4, 2004
Residence: City Kyoto	State	Country Japan	Citizenship Japanese
c/o CENTRAL F	RESEARCH LABORATORIE	S, KAKEN PHARMACEUT	TICAL CO., LTD. of
Mailing Address: 14, Shinomiya	minamigawara-cho, Ya	amashina-ku, Kyoto-	-shi, Kyoto 607-8042 Japan
			Country Japan

NAME OF SIXTH INVENTOR:				
Given Name (first and middle [if any]) Hiro	aki	Family Name or Surnam	e N	SEJISHIMA
Inventor's Signature //	iroaki Nejishima		Date	November 4, 2004
Residence: City Kyoto	State PESTAPON LABORATION	Country Japan		Citizenship Japanese
Mailing Address: 14, Shinomiy	RESEARCH LABORATORI yaminamigawara-cho,	Yamashina-ku, Kyot	EUTICA to-shi	L CO., LTD. of ., Kyoto 607-8042 Japan
City Kyoto	State	Zip 607-8042		Country Japan
NAME OF SEVENTH INVENTOR	<b>{:</b>			
Given Name (first and middle [if any])		Family Name or Surname		
Inventor's Signature			Date	
Residence: City	State	Country		Citizenship
Mailing Address:	Т	Т		
City	State	Zip		Country
NAME OF EIGHTH INVENTOR:				
Given Name (first and middle [if any])		Family Name or Surname	e	
Inventor's Signature	T	1	Date	
Residence: City	State	Country		Citizenship
Mailing Address:	Y	r		
City	State	Zip		Country
NAME OF NINTH INVENTOR:				
Given Name (first and middle [if any])		Family Name or Surname	<del>-</del>	
Inventor's Signature	·		Date	
Residence: City	State	Country		Citizenship
Mailing Address:		_		
City	State	Zip		Country
NAME OF TENTH INVENTOR:				
Given Name (first and middle [if any])		Family Name or Surname		
Inventor's Signature			Date	
Residence: City	State	Country		Citizenship
Mailing Address:				
City	State	Zip		Country

MODIFIED Form PTO-1595 RE	ECORDATION FORM COVER SHEET	U.S. DEPARTMENT OF COMMERCI
(Rev. 10/02)	PATENTS ONLY	U.S. Patent and Trademark Office
To the Director of the U.S. Patent an	nd Trademark Office: Please record the attached origina	al documents or copy thereof.
1. Name of conveying party(ies)	2. Name and address of receiving	ing party(ies):
Motonori MIYAKAWA	KAKEN PHARMACEUTICAL	L CO., LTD.
Yuji SUMITA	28-8, Honkomagome 2-chome,	
Kazuyuki FURUYA Kiyonoshin ICHIKAWA	Bunkyo-ku, Tokyo	
Kiyonoshin ICHIKAWA	113-8650 Japan	
Noriko YAMAMOTO Keigo HANADA	<i>y</i> /	
Keigo HANADA Seiji AMANO	<i>'</i>	
Hiroaki NEJISHIMA	1	
IIII OGAI I TANAGARITA.	· ·	
Additional name(s) of conveying party(ies) attached?	?□Yes ☑ No	
3. Nature of conveyance:		
☑ Assignment ☐ Merger		
☐ Security Agreement ☐ Change of Nan	me	
Other		
Execution Date: November 4, 2004	Additional name(s) & address(es) at	attached?  Yes  No
4. Application number(s) or patent number(s)	3):	Macheu: La 165 La 140
-	th a new application, the execution date of the appl	olication is: November 4, 2004
A. Patent Application No.(s) This For	rm 1595 is B. Patent No.(s)	
being filed with a new application. T	Therefore, no	
U.S. Application No. has been assigned	ned.	
Additi	tional numbers attached?	
5. Name and address of party to whom corres	spondence 6. Total number of applications	
concerning document should be mailed:		1
SUGHRUE MION, PLLC	7. Total fee (37 CFR 3.41):	\$40.00
WASHINGTON OFFICE	☑ Enclosed.	
23373	<u> </u>	to Deposit Account No. 19-4880.
CUSTOMER NUMBER	The USPTO is directed and a	authorized to charge all required
ı	fees, except for the Issue Fee and	d the Publication Fee, to Deposit
	Account No. 19-4880. Please als	lso credit any overpayments to said
	Deposit Account.	
	8. Deposit Account Number:	
		9-4880 page if paying by deposit account)
	DO NOT USE THIS SPACE	page if paying by deposit accounts
9. Statement and signature.	DO NOT USE THIS STACE	
•	The state of the s	C.I.
original document.	e foregoing information is true and correct and any	y attached copy is a true copy of the
117 /		
Susan Illant	D	December 17, 2004
Susan J. Mack	Reg. No. 30,951	Date
Total number of pa	ages including cover sheet, attachments, and docur	ments: 4
Mail documents to	o be recorded with required cover sheet informa	nation to:
MAIL STOI	P ASSIGNMENT RECORDATION SERVICE	£S .
Direct	ctor of the U.S. Patent and Trademark Office	
	P.O. Box 1450	
	Alexandria, VA 22313-1450	

## Assignment

Whereas, I/W	e, Motonori	MIYAKAWA of
c/o CENTRAL RESEA	ARCH LABORATOR	RIES, KAKEN PHARMACEUTICAL CO., LTD. of , Yamashina-ku, Kyoto-shi, Kyoto 607-8042 Japan
14, Shinomiyamin	amigawara-cho	, Yamashina-ku, Kyoto-shi, Kyoto 607-8042 Japan
neremarter carred ass	ignor(s), nave in	ivented certain improvements in
ANDROGEN REC	EPTOR AGONIST	'S
and executed an appli	ication for Lette	rs Patent of the United States of America therefor on
November 4, 200		is rate of the office brates of rimerica merelor of
1, 200	, and	•
Whereas,		KAKEN PHARMACEUTICAL CO., LTD.
•		of 28-8, Honkomagome 2-chome,
		Bunkyo-ku, Tokyo 113-8650 Japan
		•
		the entire right, title, and interest in the application and atents to be obtained therefor;
	<del>-</del>	onsideration, receipt whereof is hereby acknowledged,
I/We, the above	ve named assign	or(s), hereby sell, assign and transfer to the above named
assignee, its successor	rs and assigns, tl	he entire right, title and interest in the application and the
invention disclosed th	erein for the Un	ited States of America, including the right to claim priority
under 35 U.S.C. §119	, and I/we reque	est the Director - U.S. Patent and Trademark Office to issue
		evention set forth in the application to the assignee, its
		execute without further consideration all papers deemed
		on with the United States application when called upon to
do so by the assignee.		
		uest our attorneys SUGHRUE MION, PLLC of 2100
		ton, DC 20037-3213 to insert here in parentheses
(Application number	•	and Confirmation number
	, filed _	
and application numb	er of said applic	ation when known.
		<i>"</i>
Date: // 0/20	115	Migutiner .
Date: 11/4/04	100	i juliani
	s/ Motonori	MIYAKAWA
Date:		
	s/	
	2/	
Date:		
	s/	
Dotai		
Date:		

## Assignment

Whereas, I/We, Keigo HA		_ of
2-1-38, Hirai, Kusatsu-shi hereinafter called assignor(s), have ANDROGEN RECEPTOR AGONIST:	invented certain improvements in	
THE ROOM RECEIVED TOWN AGONTS I		
and executed an application for Let November 4, 2004; and	iters Patent of the United States of America therefor on	
Whereas,	KAKEN PHARMACEUTICAL CO., LTD.	
·	of 28-8, Honkomagome 2-chome,	
	Bunkyo-ku, Tokyo 113-8650 Japan	
		•
(assignee), desires to acquir invention, and to any United States	e the entire right, title, and interest in the application and patents to be obtained therefor;	
Now therefore, for valuable	consideration, receipt whereof is hereby acknowledged,	
invention disclosed therein for the under 35 U.S.C. §119, and I/we required any Letters Patent granted upon the successors and assigns; and I/we was	the entire right, title and interest in the application and the United States of America, including the right to claim prioquest the Director – U.S. Patent and Trademark Office to is invention set forth in the application to the assignee, its ill execute without further consideration all papers deemed the control with the United States application when called upon	rity ssue
	request our attorneys SUGHRUE MION, PLLC of 2100	
	ngton, DC 20037-3213 to insert here in parentheses and Confirmation number	
, file	d ) the filing date	;
and application number of said app		
Date: November 4, 2004	eign Hanada	
s/ Keigo I	ANADA	
Date:		
S/		
Date:		
s/ Date:		

# Assignment

	We, Yuji SUMITA, Kazuyuki FURUYA, Kiyonoshin ICHIKAWA,
	TO, Seiji. AMANO and Hiroaki NEJISHIMA of c/o CENTRAL RESEARCH
	KAKEN PHARMACEUTICAL CO., LTD. of 14, Shinomiyaminamigawara-cho,
Yamashina-ku,	Kyoto-shi, Kyoto 607-8042 Japan, respectively,
hereinafter called a	ssignor(s), have invented certain improvements in CEPTOR AGONISTS
and executed an ap	plication for Letters Patent of the United States of America therefor on; and
Whereas,	KAKEN PHARMACEUTICAL CO., LTD. of 28-8, Honkomagome 2-chome
	Bunkyo-ku, Tokyo 113-8650 Japan
(assignee), of invention, and to an	desires to acquire the entire right, title, and interest in the application and by United States patents to be obtained therefor;
Now therefor	ore, for valuable consideration, receipt whereof is hereby acknowledged,
assignee, its successinvention disclosed under 35 U.S.C. §1 any Letters Patent g successors and assignee.	sors and assigns, the entire right, title and interest in the application and the therein for the United States of America, including the right to claim priority 19, and I/we request the Director – U.S. Patent and Trademark Office to issue granted upon the invention set forth in the application to the assignee, its gns; and I/we will execute without further consideration all papers deemed signee in connection with the United States application when called upon to see.
Pennsylvania Aven (Application number	authorize and request our attorneys SUGHRUE MION, PLLC of 2100 ue, NW, Washington, DC 20037-3213 to insert here in parentheses er and Confirmation number, filed) the filing date nber of said application when known.
and approacton nur	tool of said application when known.
Date: November 4	, 2004 Yuji Sumita
	s. Yuji SUMITA  , 2004 Kazuyuki Furuya  s. Kazuyuki FURUYA
	s/ Kiyonoshin Ichikawa
Data	2004 NOTIKO Yamamoto s/ Notiko Yamamoto
Date: November 4,	2004 Seiji Amano S. Seiji AMANO
Date: November 4,	2004 Hiroaki Nejishima S Hiroaki Nejishima
Date:	a uliodri Mediculu